ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $25.56 Consensus Target Price from Analysts

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have received a consensus rating of “Moderate Buy” from the seventeen ratings firms that are covering the company, MarketBeat reports. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $25.56.

Several brokerages have recently issued reports on ACAD. UBS Group reduced their price target on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Raymond James reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. Cantor Fitzgerald reduced their price objective on ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 10,329 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $173,630.49. Following the completion of the sale, the chief operating officer now owns 62,105 shares in the company, valued at approximately $1,043,985.05. The trade was a 14.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Mark C. Schneyer sold 10,259 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the transaction, the chief financial officer now owns 53,302 shares in the company, valued at approximately $896,006.62. This trade represents a 16.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,661 shares of company stock valued at $414,551. 28.30% of the stock is currently owned by insiders.

Institutional Trading of ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. M&G Plc acquired a new position in ACADIA Pharmaceuticals in the first quarter valued at $5,622,000. SG Americas Securities LLC increased its position in ACADIA Pharmaceuticals by 246.7% in the 1st quarter. SG Americas Securities LLC now owns 84,956 shares of the biopharmaceutical company’s stock valued at $1,571,000 after acquiring an additional 60,452 shares during the period. Fred Alger Management LLC raised its stake in ACADIA Pharmaceuticals by 19.8% during the 2nd quarter. Fred Alger Management LLC now owns 2,704,439 shares of the biopharmaceutical company’s stock valued at $43,947,000 after acquiring an additional 446,875 shares during the last quarter. US Bancorp DE raised its stake in ACADIA Pharmaceuticals by 2,084.0% during the 3rd quarter. US Bancorp DE now owns 32,934 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 31,426 shares during the last quarter. Finally, Sei Investments Co. lifted its position in ACADIA Pharmaceuticals by 6.2% during the 1st quarter. Sei Investments Co. now owns 34,752 shares of the biopharmaceutical company’s stock worth $642,000 after acquiring an additional 2,034 shares during the period. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Trading Down 4.8 %

ACADIA Pharmaceuticals stock opened at $16.21 on Wednesday. The stock has a market cap of $2.70 billion, a P/E ratio of 20.78 and a beta of 0.38. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $32.59. The company has a 50-day moving average price of $15.60 and a 200 day moving average price of $15.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business had revenue of $250.40 million during the quarter, compared to analysts’ expectations of $248.83 million. During the same period in the previous year, the firm posted ($0.40) earnings per share. The company’s revenue was up 18.3% on a year-over-year basis. As a group, analysts forecast that ACADIA Pharmaceuticals will post 0.72 EPS for the current year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.